MAP2K1 and thyroid gland carcinoma: These data show that in a panel of BRAF-mutant advanced thyroid cancer cell lines sensitive or resistant to MEKi, most, but not all, exhibit moderate to strong synergistic inhibition of cell viability in response to combined BRAF/MEK1/2 inhibition.